The outcome of patients with relapsed B-ALL has considerably improved with CD19 targeting CAR T cells and BiTEs, and the CD22 ADC InO has contributed to this progress. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.